The FDA finally approved Eli Lilly’s Tirzepatide
for weight management/weight loss!!
Tirzepatide is what Mounjaro is… a Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP).
This is so wonderful, there are hardly words.
Mounjaro was approved in 2022 for people with Type 2 Diabetes. Because tirzepatide, the active ingredient in Mounjaro, is more effective than semaglutide (Ozempic/Wegovy), the news about Zepbound, also a GLP-1/GIP is phenomenal!
Note: Novo Nordisk started the same way as Eli Lilly did with Mounjaro, making Wegovy for Type 2 Diabetics then getting FDA approval for Ozempic, the same semaglutide, but for weight management.
(Selfishly, I am glad they gave the medication a new name so Mounjaro will be reserved for Type 2 Diabetics.)
From Eli Lilly’s News Release:
Zepbound is expected to be available in the U.S. by the end of the year in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) at a list price of $1,059.87, which is approximately 20% lower than semaglutide 2.4 mg injection for weight loss. List price does not reflect the typical out-of-pocket cost to patients given insurance coverage and discounts. Lilly is putting a commercial savings card program in place that will help people who may benefit from Zepbound better access it.
People who are commercially insured with coverage for Zepbound may be eligible to pay as low as $25 for a 1-month or 3-month prescription.
People who are commercially insured without coverage for Zepbound may be eligible to pay as low as $550 for a 1-month prescription of Zepbound, approximately 50% lower than the list price.
People may begin using the savings card program in the days following product availability at U.S. pharmacies.
More to come soon! But for now…
CELEBRATE!!!
